pharma news, views and analysis - pharmaphorum.com

Trending

in News
FDA grants fast review to BMS’ first-line lung cancer combo
January 16, 2020 Share
X
FDA grants fast review to BMS’ first-line lung cancer combo
https://pharmaphorum.com/news/fda-grants-fast-review-to-bms-first-line-lung-cancer-combo/
in News
Clovis takes PARP prostate cancer pole position with fast FDA review of Rubraca
January 15, 2020 Share
X
Clovis takes PARP prostate cancer pole position with fast FDA review of Rubraca
https://pharmaphorum.com/news/clovis-takes-parp-prostate-cancer-pole-position-with-fast-fda-review-of-rubraca/

Latest News

UK accounts for 12% of cell and gene therapy trials – report

UK accounts for 12% of cell and gene therapy trials – report

The UK accounts for over 12% of global cell and gene therapy clinical trials, according to new data

X

UK accounts for 12% of cell and gene therapy trials – report

https://pharmaphorum.com/news/uk-accounts-for-12-of-cell-and-gene-therapy-trials-report/

NICE rejects Astellas’ Xospata in AML, queries MSD’s Keytruda evidence in HNSCC

NICE rejects Astellas’ Xospata in AML, queries MSD’s Keytruda evidence in HNSCC

NICE has been busy with announcements today, rejecting Astellas’ Xospata for a certain type of acute myeloid leukaemia

X

NICE rejects Astellas’ Xospata in AML, queries MSD’s Keytruda evidence in HNSCC

https://pharmaphorum.com/news/nice-rejects-astellas-xospata/

MorphoSys gets $750m from Incyte for anti-CD19 cancer drug

MorphoSys gets $750m from Incyte for anti-CD19 cancer drug

Incyte has agreed a deal with Germany’s MorphoSys to license an antibody that could be an alternative to

X

MorphoSys gets $750m from Incyte for anti-CD19 cancer drug

https://pharmaphorum.com/news/morphosys-gets-750m-from-incyte-for-anti-cd19-cancer-drug/

Views & analysis

Sanofi Genzyme UK medical boss Marc Moodley discusses oncology plans, NICE and Brexit

Sanofi Genzyme UK medical boss Marc Moodley discusses oncology plans, NICE and Brexit

Marc Moodley has worked at Sanofi since 2018 and is the new medical head, UK and Ireland for

X

Sanofi Genzyme UK medical boss Marc Moodley discusses oncology plans, NICE and Brexit

https://pharmaphorum.com/views-analysis-oncology/sanofi-genzyme-uk-medical-boss-marc-moodley-discusses-oncology-plans-nice-and-brexit/

Pfizer and the UK cancer landscape: the pharmaphorum podcast

Pfizer and the UK cancer landscape: the pharmaphorum podcast

Pfizer’s Dr Olivia Ashman joined me for episode 16 of the pharmaphorum podcast, which focuses on the UK

X

Pfizer and the UK cancer landscape: the pharmaphorum podcast

Q&A: Avacta’s Amrik Basran on immunotherapy

Q&A: Avacta’s Amrik Basran on immunotherapy

Dr Amrik Basran from Avacta explains the current state of cancer immunotherapy and the challenges of moving into

X

Q&A: Avacta’s Amrik Basran on immunotherapy

https://pharmaphorum.com/views-analysis-oncology/avactas-amrik-basran-on-immunotherapy/

Debates & Insights

Cost & Management of Oncology Combination Regimens

Cost & Management of Oncology Combination Regimens

Overview Oncology treatment increasingly involves combinations of novel oral and biologic drugs. While combo approaches aren’t new, there

X

Cost & Management of Oncology Combination Regimens

https://pharmaphorum.com/oncology/cost-management-of-oncology-combination-regimens/

Cancer, genomics and personalised medicine: Modelling oncology’s future

Cancer, genomics and personalised medicine: Modelling oncology’s future

Overview The prevalence of cancer is currently predicted to be higher than ever. Current statistics show 1 in

X

Cancer, genomics and personalised medicine: Modelling oncology’s future

https://pharmaphorum.com/oncology/cancer-genomics-and-personalised-medicine-modelling-the-future-of-oncology/

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

11/06/2017

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

A unique example of partnership working across the health system, focusses on the service at large, not just the pill, and uses leading-edge data analytics to analyse, benchmark and visualise the current state of the cancer pathways within the Cancer Vanguard Trusts. Furthermore, it encompasses multiple aspects of the service provision ranging from patient outcomes and experiences, the flow of treatment and the usage of medicine in order to inform an evidence-based and patient-centric approach to service redesign and resource optimisation.

X

Improving Outcomes Through Industry Partnership – Learnings from the Cancer Vanguard

https://pharmaphorum.com/debates-insight-oncology/improving-outcomes-through-industry-partnership-learnings-from-the-cancer-vanguard/

Partner Content

Oncology Forecasting Training New Jersey

Oncology Forecasting Training New Jersey

A dedicated 1 day Oncology Forecasting Training Course

X

Oncology Forecasting Training New Jersey

https://pharmaphorum.com/events/oncology-forecasting-training-new-jersey/

Attendee List Released for SMi’s 9th Annual RNA Therapeutics

Attendee List Released for SMi’s 9th Annual RNA Therapeutics

RNA Therapeutics

X

Attendee List Released for SMi’s 9th Annual RNA Therapeutics

https://pharmaphorum.com/partner-content-oncology/attendee-list-released-for-smis-9th-annual-rna-therapeutics/

RNA Therapeutics conference will take place in just 4 weeks!

RNA Therapeutics conference will take place in just 4 weeks!

4 Weeks Until RNA Therapeutics

X

RNA Therapeutics conference will take place in just 4 weeks!

https://pharmaphorum.com/partner-content-oncology/rna-therapeutics-conference-will-take-place-in-just-4-weeks/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com